Landmark Bio Secures Up to $18.3 Million ARPA-H Award to Build a Scalable Continuous Manufacturing Platform for Extracellular Vesicle Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)--Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of next-generation advanced therapies from discovery to clinical and commercial production, today announced that it has secured an Advanced Research Projects Agency for Health (ARPA-H) award totaling…
Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston
Expanded facility integrates Syngoi Technologies’ enzymatic DNA platform into Artis’ North American operations, ensuring resilient, U.S.-based, clinical-grade supply chains for advanced therapies SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--Artis BioSolutions (“Artis”), an advanced therapies company dedicated to integrating the specialized…
Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology
SAN DIEGO & BOSTON & BILBAO, Spain--(BUSINESS WIRE)--Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic…
Landmark Bio Forges New Collaboration to Accelerate Early-Stage Translational Cell and Gene Therapies
Agreement establishes framework for advancing Mass General Brigham-originated cell and gene therapies. Landmark Bio to support early-stage development and manufacturing through collaboration with Mass General Brigham’s Gene and Cell Therapy Institute.
Landmark Bio Acquired by Artis BioSolutions to Expand Manufacturing and Commercialization of Advanced Therapies
Acquisition enables Landmark Bio to scale capabilities to accelerate development and manufacturing of advanced therapies. Artis BioSolutions to provide strategic investment to build technology and operations. Company to continue operating independently, leveraging position in Massachusetts’ life sciences ecosystem
ChromaTan and Landmark Bio Awarded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Grant to Advance Intensified Recombinant Adeno-Associated Virus (AAV) Production Process
Grant allows ChromaTan and Landmark Bio to create a scalable, cost-effective, and accessible platform for the manufacturing and characterization of AAV-based gene therapy vectors. Project developed with award from NIIMBL and financial assistance from the National Institute of Standards and Technology.
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos’ Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos’ CAR-T product candidates in the Boston area
Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research
Landmark Bio will serve as strategic partner in the development and manufacturing of InnDura’s pipeline products
Landmark Bio Unveils New State-of-the-Art Full-Spectrum Biomanufacturing Innovation Center
New 44,000 square-foot fully integrated facility for development, manufacturing and testing of cell and gene therapies in Watertown, Massachusetts, offers end-to-end capabilities and onestop manufacturing solutions
Landmark Bio Appoints Gregg Nyberg, Ph.D., as Chief Technology Officer and Michael Covington as Chief Quality and Regulatory Officer
Newest members of Landmark Bio’s executive team bring decades of industry leadership and expertise in drug development and biomanufacturing
Introducing Landmark Bio and Appointment of Ran Zheng as CEO
Zheng will lead the construction of the new, state-of-the-art biomanufacturing facility that kicks off today (July 29) in Watertown, MA and will begin opening in 2022.